Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Gaps in Knowledge (1 of 3)
Evidence is insufficient to evaluate potential associations between bisphosphonate use and either esophageal cancer or atrial fibrillation. However, an FDA safety review notes that a relationship between zoledronic acid and atrial fibrillation is still an area of active surveillance, though an association is unproven.
Evidence for the antifracture effects of currently available osteoporosis therapies is greatest among patients with established osteoporosis, and few head-to-head comparisons of medications exist. Studies comparing exercise with medications are lacking.
Keywords: bone | low bone density | bone density | osteoporosis | fracture | osteopenia | skeletal | bisphosphonate | esophageal cancer | atrial fibrillation | zoledronic acid | osteoporosis | antifracture | surveillance | exercise
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.